Charles Heacock, OD
Optometrist · Deland, FLNPI 1942294905
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,325 of the $1,825 with a category attached, or 72.6%. 9 manufacturers reported payments, led by Glaukos Corporation at 33.7% of the total. Reporting peaked in 2019 at $963 and has fallen 89.9% since, to $97 in 2025.
Across 42 payments — averaging $43.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$615
- Alcon$458
- Coopervision Inc.$253
- Johnson & Johnson Vision Care, Inc.$223
- Oyster Point Pharma, Inc.$120
- Bausch & Lomb, A Division Of Bausch Health US, LLC$112
- plus $44 from 3 others
What the payments were for
- Consulting fees$50027%
- Food & beverage$1,32573%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 2 | $615 |
| Alcon | 15 | $458 |
| Coopervision Inc. | 8 | $253 |
| Johnson & Johnson Vision Care, Inc. | 7 | $223 |
| Oyster Point Pharma, Inc. | 1 | $120 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $112 |
| Dompe US, Inc. | 1 | $17 |
| Bausch & Lomb Americas Inc. | 1 | $14 |
| Biotissue Holdings Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Acuvue$122
- TYRVAYA$120
- MyDay Contact Lens$112
How this compares
$1,825 in reported general payments places this provider in the 65th percentile of 3,166 optometrist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CombiganBrimonidine Tartrate/Timolol | 13 | $2,545 |
| Latanoprost | 274 | $2,362 |
| Travoprost | 15 | $1,717 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 56 | $1,230 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 64 | $1,111 |
| Timolol Maleate | 56 | $869 |
| Fluorometholone | 20 | $678 |
| Dorzolamide Hcl | 27 | $621 |
| Prednisolone Acetate | 11 | $287 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Deland
- James HoffmanOrange Park$795K
- April JasperWest Palm Beach$553K
- Nora CothranLargo$505K
- Michael SluskyNorth Port$384K
- Katie SpearDefuniak Springs$361K
- Karen HoffmanOrange Park$282K
- Ashley RothMiami Beach$261K
- Jessica SteenDavie$256K
- Mark DunbarMiami$236K
- Robert DavisPembroke Pines$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.